MoonLake Immunotherapeutics (MLTX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Zug, Switzerland. El CEO actual es Jorge Santos da Silva.
MLTX tiene fecha de IPO 2020-10-20, 100 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $1.35B.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
